Free Trial
NASDAQ:QNRX

Quoin Pharmaceuticals Q4 2024 Earnings Report

Quoin Pharmaceuticals logo
$6.60 -0.52 (-7.30%)
Closing price 04/28/2025 03:51 PM Eastern
Extended Trading
$6.76 +0.17 (+2.50%)
As of 04/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quoin Pharmaceuticals EPS Results

Actual EPS
-$12.25
Consensus EPS
-$17.50
Beat/Miss
Beat by +$5.25
One Year Ago EPS
N/A

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quoin Pharmaceuticals' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Quoin Pharmaceuticals Earnings Headlines

Quoin Pharmaceuticals Ltd – ADR trading halted, news pending
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

View Quoin Pharmaceuticals Profile

More Earnings Resources from MarketBeat